View Header


Office of the Press Secretary

For Immediate Release May 1, 1995


The President today announced his intent to appoint Dr. Paul Calabresi to the President's Cancer Panel.

Paul Calabresi, M.D., M.A.C.P. of Rhode Island served as Chairman of the National Cancer Advisory Board of the National Cancer Institute, a position he assumed in 1991. Dr. Calabresi is currently Professor of Medicine and Chairman Emeritus of the Department of Medicine at Brown University School of Medicine and Chairman of the Research Advisory Committee at Rhode Island Hospital. He is a Fellow of the Institute of Medicine of the National Academy of Sciences and a Master of the American College of Physicians.

Dr. Calabresi is a graduate of Yale College and Yale University School of Medicine. He was a Resident on the Harvard Medical Services at Boston City Hospital. He was on the faculty at Yale University School of Medicine before coming to Brown University School of Medicine. Dr. Calabresi has served as President of the American Society of Clinical Oncology and on the Board of Directors of the American Association for Cancer Research, and is currently President of the New England Cancer Society. He is an Associate Editor of the journal Cancer of the American Cancer Society, he has served on the editorial board of the New England Journal of Medicine, and has also been an Editorial Consultant in Oncology for the Journal of the American Medical Association.

Dr. Calabresi is an internationally recognized medical oncologist and authority on the pharmacology of anticancer agents. He has been awarded the Oscar B. Hunter Memorial Award in Therapeutics from the American Society of Clinical Pharmacology and Therapeutics and the St. George medal for distinguished volunteer service from the American Cancer Society. He is a member and has been an officer of several professional societies and prominent committees of the National Cancer Institute. Dr. Calabresi has authored or edited more than 200 manuscripts and books on the management of cancer and the pharmacology of anticancer agents.

The President's Cancer Panel serves as a liaison between the National Cancer Program and the President. Composed of primarily scientists and physicians, it is designed to monitor the development and execution of the activities of the National Cancer Program, and reports directly to the President. The Panel submits periodic reports to the President, and is responsible for alerting the President to any delays or blockages in the rapid execution of the National Cancer Program.